Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.533
Abstract: 533Background: Sorafenib or lenvatinib are the current frontline options for advanced HCC. Multiple biologic agents including multi-Tyrosine Kinase Inhibitors (TKI) cabozantinib & regorafenib have ... read more here.
Keywords: biologics second; immunotherapy versus; therapy advanced; versus biologics ... See more keywords